Global The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. Last year, orphan drugs accounted for more than a third of Europe’s new drug approvals, and the number of gene…
See our Cookie Privacy Policy Here
